NasdaqGM - Nasdaq Real Time Price USD

Inventiva S.A. (IVA)

3.5007

-0.0093

(-0.26%)

At close: May 14 at 4:00:00 PM EDT

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with si

GlobeNewswire 10 days ago

IVA
-0.26%

IVEVF
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com DateNumber of shares outstandingTotal voting rights,gross (1)Total voting rights,net (2)April 11, 202595,662,391108,635,435108,574,827 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis

GlobeNewswire 14 days ago

IVA
-0.26%

IVEVF
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Daix (France), New York City (New York, United States), April 30, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Me

GlobeNewswire 14 days ago

IVA
-0.26%

IVEVF
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► The biomarker signatures suggested strong predictive accuracy, with AUROC values above 0.80 that may indicate hig

GlobeNewswire 20 days ago

IVA
-0.26%

IVEVF
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December 31, 2024,

GlobeNewswire 29 days ago

IVA
-0.26%

IVEVF
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

Here is how Elicio Therapeutics (ELTX) and Inventiva S.A. Sponsored ADR (IVA) have performed compared to their sector so far this year.

Zacks last month

ELTX

IVA.PA
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small mol

GlobeNewswire last month

IVA
-0.26%

IVEVF
Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...

Despite a significant net loss, Inventiva SA (IVEVF) strengthens its financial position and advances its clinical trials for lanifibranor.

GuruFocus.com last month

IVA.PA
Inventiva reports its 2024 full year results and provides a business update

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and r

GlobeNewswire last month

IVA
-0.26%

IVEVF
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2024 full-year financial re

GlobeNewswire last month

IVA
-0.26%

IVEVF
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PHLanifibranor was observed to decrease portal pressure by improving Liver Sinusoidal Endothelial Cell (LSEC) dysfunction and fibrosis, and by directly targeting the splanchnic vasculature through its anti-angiogenetic effectsThese findings suggest that lanifibranor may be a promising therapeutic candidate that could potentially address PH-related complications ty

GlobeNewswire 2 months ago

IVA
-0.26%

IVEVF
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 studyPositive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASHThe study represents the first significant step of Inventiva’s and Hepalys’s partnership toward the development of lanifibranor in Japan and South Korea Daix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025 – Inventiva (Euronext Pari

GlobeNewswire 2 months ago

IVA
-0.26%

IVEVF
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early January 2025 and randomization of the last patient expected within the first half of 2025Pipeline prioritization plan presented to the workers council to focus exclusively on the develo

GlobeNewswire 3 months ago

IVA
-0.26%

IVEVF
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with MASLD and T2DA significantly higher proportion of patients achieved a greater than 30% liver triglyceride reduction as well as MASLD resolution with lanifibranor compared to placeboLanifibranor treatment significantly improved both hep

GlobeNewswire 3 months ago

IVA
-0.26%

IVEVF
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contr

GlobeNewswire 3 months ago

IVA
-0.26%

IVEVF
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that the results from its Proof-of-Concept trial evaluating lanifibranor in combination with em

GlobeNewswire 3 months ago

IVA
-0.26%

IVEVF
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, ha

GlobeNewswire 4 months ago

IVA
-0.26%

IVEVF
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. Proceeds from the completed first tranche to be primarily used to advance Inventiva’s Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of D

GlobeNewswire 4 months ago

IVA
-0.26%

IVEVF
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’

GlobeNewswire 4 months ago

IVA
-0.26%

IVEVF
Inventiva reports 2024 Third Quarter Financial Information¹

Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 20242 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on

GlobeNewswire 5 months ago

IVA
-0.26%

IVEVF

Performance Overview

Return	IVA	CAC 40 (^FCHI)
YTD	+54.22%	+5.96%
1-Year	-4.09%	-5.09%
3-Year	-60.22%	+22.91%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Inventiva S.A. (IVA)

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva SA (IVEVF) (Q4 2024) Earnings Call Highlights: Navigating Financial Challenges and ...

Inventiva reports its 2024 full year results and provides a business update

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

Inventiva reports 2024 Third Quarter Financial Information¹

Performance Overview